BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 7788073)

  • 1. Current issues in hypertension research and therapy.
    MacFadyen RJ; Prasad N
    Br J Hosp Med; 1995 Apr 5-18; 53(7):335-43. PubMed ID: 7788073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of changes in blood pressure and left ventricular mass induced by antihypertensive treatment on ventricular arrhythmias in essential hypertension.
    Muiesan ML; Zulli R; Rizzoni D; Calebich S; Malerba M; Porteri E; Agabiti-Rosei E
    J Hypertens Suppl; 1993 Dec; 11(5):S104-5. PubMed ID: 8158296
    [No Abstract]   [Full Text] [Related]  

  • 3. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Rational hypertension treatment].
    Canova CR
    Schweiz Med Wochenschr; 1996 Aug; 126(33):1394-9. PubMed ID: 8830397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of hypertension in chronic kidney disease.
    Toto RD
    Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydropyridines versus other agents in the treatment of hypertension in the elderly. Part 1: Antihypertensive therapy and left ventricular hypertrophy.
    Fagard R; Staessen J; Thijs L; Van Hoof R; Amery A
    J Hypertens Suppl; 1993 Dec; 11(6):S27-9. PubMed ID: 7909547
    [No Abstract]   [Full Text] [Related]  

  • 7. [Recent intervention studies with antihypertensive drugs and their influence on guidelines].
    Rahn KH
    Med Klin (Munich); 2003 Dec; 98(12):771-5. PubMed ID: 14685679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antihypertensive treatment for patients with hypertension and diabetes type II--current clinical research].
    Rajzer M; Kawecka-Jaszcz K; Wojciechowska W
    Przegl Lek; 2003; 60(2):111-5. PubMed ID: 12939858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive therapy in the presence of proteinuria.
    Sarafidis PA; Khosla N; Bakris GL
    Am J Kidney Dis; 2007 Jan; 49(1):12-26. PubMed ID: 17185142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. More is less? Optimal combination therapy for adequate blood pressure lowering in hypertension.
    Kjeldsen SE; Hedner T; Narkiewicz K; Oparil S
    Blood Press; 2008; 17(3):132-3. PubMed ID: 18665471
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade.
    Weir MR
    J Hum Hypertens; 2007 Oct; 21(10):770-9. PubMed ID: 17597800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Risk factors to be considered at the beginning of antihypertensive therapy in diabetes mellitus].
    Jermendy G
    Orv Hetil; 2004 May; 145(18):949-56. PubMed ID: 15188641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of the selective blocking of angiotensin II receptors in the treatment of cardiovascular diseases].
    Carnovali M
    Clin Ter; 2001; 152(2):103-6. PubMed ID: 11441521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction of hypertensive cardiac remodelling: comparison of different antihypertensive therapies.
    Almazov VA; Shlyakhto EV; Konrady AO; Macsimova TA; Zaharov DV; Rudomanov OG
    Med Sci Monit; 2000; 6(2):309-13. PubMed ID: 11208328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Improving the control of systolic hypertension and pulse pressure in elderly population].
    Sun N
    Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(21):1441-2. PubMed ID: 12645505
    [No Abstract]   [Full Text] [Related]  

  • 18. Systolic hypertension.
    Nash DT
    Geriatrics; 2006 Dec; 61(12):22-8. PubMed ID: 17184139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation and management of hypertension in children and adolescents (part two): evaluation and management.
    Cromwell PF; Munn N; Zolkowski-Wynne J
    J Pediatr Health Care; 2005; 19(5):309-13. PubMed ID: 16202839
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review.
    Dahlöf B
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S37-44. PubMed ID: 8583480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.